John W. Rogers Jr.
Ariel Appreciation Fund
John W. Rogers Jr. Core Laboratories NV stake
total: 70
Ariel Appreciation Fund CLB trades
- Total transactions:
- 13
- New positions:
- 1
- Added:
- 7
- Reduced:
- 5
- Held since:
- 2021 Q4
- Held for:
- 18 quarters
- Latest activity:
- 2025 Q3
According to 2026 Q1 report, John W. Rogers Jr. holds 1,513,465 Core Laboratories NV (CLB) shares with a market value of roughly $25.41M accounting for 2.91% of the overall portfolio. To date, the estimated cost basis is nearly $20.42 for "buy" trades and estimated average "sell" price is $17.55. Ariel Appreciation Fund first purchased CLB in 2021 Q4, initially acquiring 854,272 shares. Since the initial investment in Core Laboratories NV (CLB), Ariel Appreciation Fund has made 12 more transactions.
When did John W. Rogers Jr. buy Core Laboratories NV (CLB)?
John W. Rogers Jr. first invested in Core Laboratories NV (CLB) in 2021 Q4 at the reported quarter-end price of $22.31 per share.
What's the cost basis of Ariel Appreciation Fund's CLB stake?
The estimated cost basis for Core Laboratories NV (CLB) stake is around $20.42 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $20.42
- Weighted AVG sell price:
- $17.55
John W. Rogers Jr.'s historical trades in Core Laboratories NV
13 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q3
|
2.09%
|
1,513,465
|
$12.36
|
$18,706,427
|
+10.58% (+144,838)
|
+0.2%
|
|
2025 Q2
|
1.86%
|
1,368,627
|
$11.52
|
$15,766,583
|
-7.89% (-117,273)
|
-0.16%
|
|
2025 Q1
|
2.62%
|
1,485,900
|
$14.99
|
$22,273,641
|
+7.50% (+103,657)
|
+0.18%
|
|
2024 Q4
|
2.50%
|
1,382,243
|
$17.31
|
$23,926,626
|
-10.44% (-161,092)
|
-0.28%
|
|
2024 Q3
|
2.83%
|
1,543,335
|
$18.53
|
$28,597,998
|
-5.58% (-91,175)
|
-0.18%
|
|
2024 Q1
|
2.60%
|
1,634,510
|
$17.08
|
$27,917,431
|
+25.40% (+331,082)
|
+0.53%
|
|
2023 Q4
|
2.15%
|
1,303,428
|
$17.66
|
$23,018,538
|
-6.29% (-87,499)
|
-0.15%
|
|
2023 Q2
|
2.91%
|
1,390,927
|
$23.25
|
$32,339,053
|
+6.87% (+89,400)
|
+0.19%
|
|
2023 Q1
|
2.50%
|
1,301,527
|
$22.05
|
$28,698,670
|
-9.91% (-143,180)
|
-0.28%
|
|
2022 Q4
|
2.57%
|
1,444,707
|
$20.27
|
$29,284,211
|
+7.61% (+102,207)
|
+0.18%
|
|
2022 Q2
|
2.42%
|
$19.81
|
+39.50% (+380,146)
|
|||
|
2022 Q1
|
2.36%
|
$31.63
|
+12.65% (+108,082)
|
|||
|
2021 Q4
|
1.36%
|
$22.31
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.